Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibMolecular profiling in the treatment of colorectal cancer: focus on regorafenibManagement of regorafenib-related toxicities: a reviewAnti-angiogenic agents in metastatic colorectal cancerClinical management of regorafenib in the treatment of patients with advanced colorectal cancerRegorafenib in metastatic colorectal cancer.Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocolRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsDiscovery of a New Series of Naphthamides as Potent VEGFR-2 Kinase InhibitorsOptimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisRegorafenib: an evidence-based review of its potential in patients with advanced liver cancerp38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.Regorafenib: from bench to bedside in colorectal cancer.Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancerClinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal CancerQuantitative determination of regorafenib and its two major metabolites in human plasma with high-performance liquid chromatography and ultraviolet detection.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal CancerPreliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancerUpdate on Anti-Angiogenesis Therapy in Colorectal Cancer.Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.Drug monographs: bosutinib and regorafenib.Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
P2860
Q26747162-9EF36490-0857-4A1D-AD40-203A7CBBFE3BQ26778296-3BD6A775-2FCB-491B-B036-5C22ABFC2B04Q26795561-CAA8322B-291B-43BB-B9C0-91C8FC0F4646Q26801911-DF0472D4-9266-4612-B471-3D0DD8356DD1Q26821956-152836B6-01B3-47AE-8B42-B979F505E356Q27852864-3E17BB1A-FDAD-44D1-8C06-8B2C18BC2B94Q28652334-13975F0A-C7C3-4B69-89AA-B386943B4385Q30593460-C9F89501-6F62-46E4-8CFE-03CBB7E04727Q31131324-F7B19DA6-2185-4B85-9E19-E3FB207D1002Q31153869-7A2DE4A9-374C-4959-B2E4-246ED4FEF7EFQ33356339-FC5CAD72-FBD3-44B9-AC23-72FC97BB1E54Q33417630-CD70A5A7-F834-4D8D-867E-3DCA22CE21B2Q33636113-3CD35516-50AB-41C0-88EE-D1FEC106874AQ33699635-06AFB799-0035-47D9-BC82-44645DF15504Q33838524-DB4C4F09-01EA-4FF6-8687-E44F1A36F01DQ33885957-E1E702E2-7A12-4A47-9B9B-C844D4A5FFFFQ33926377-48DE4F2F-E2F2-497F-8079-8A57A7A713AAQ33944599-2578F98B-95E9-4C9F-B673-58F725136956Q34008781-37808623-B6FA-4DCB-9266-F712F6973083Q34343524-605C6B9B-422E-4DF7-AB9F-C9DFE1E68BB9Q34348270-C89EE1DF-05F2-40BF-A077-E1BB2315DCBAQ34649934-C5508333-EDEF-4E8F-A7AE-07466D677B5DQ34776150-DE500E64-8701-43FB-90EB-759426B65ADEQ35519994-FD13557E-D79B-4C00-BC90-61E12CD2A57EQ35689747-EA0126AE-0945-4911-9E22-D405DCA1C1C0Q35799832-6C9EC3B9-5362-4E7B-A6D1-C1831BAB8C55Q35869753-FCBCF279-AF98-4FB0-8AAE-7FC33F5B58F3Q35977528-C6777204-1E58-4E71-A965-D4F054E95E4FQ36078348-2AC80660-DE76-4A09-943F-5282A58D870CQ36187128-AEA9FCA9-B089-4E9F-BB32-ABF5D58873F2Q36570837-D472E45E-AD0B-43BD-ABDC-E8A41C82266CQ36843760-9C8F1B6C-BC19-4FDD-B0B0-789ECD01EA8CQ36862851-06A4F876-2B02-451C-9900-021387784F38Q37066657-C80BE2D0-4B34-450B-8E30-229EC055AAE6Q37143791-9B126CD0-54E6-435D-887C-F3D731348FE1Q37190578-10DFEB89-2C48-4CFB-92BE-7D78DFCF650DQ37211199-BC3CD79D-85B1-4A30-A9FC-8B59C973BB0CQ37340111-121E1BFB-B19C-4A6E-B38B-1BBF354D3AF0Q37429966-67462456-D821-4063-9068-10DFB503BBDBQ37554954-ED4FF99F-84BE-40E7-B0AD-10F4E7C41817
P2860
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@ast
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@en
type
label
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@ast
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@en
prefLabel
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@ast
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@en
P2093
P2860
P356
P1476
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
@en
P2093
B Schultheis
D Strumberg
M E Scheulen
O Christensen
P2860
P2888
P304
P356
10.1038/BJC.2012.153
P407
P577
2012-05-08T00:00:00Z
P5875
P6179
1016888347